Editorial
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2023; 15(12): 1253-1257
Published online Dec 27, 2023. doi: 10.4254/wjh.v15.i12.1253
From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
Li Chen
Li Chen, Department of Gastroenterology, Ruijin Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai 201801, China
Author contributions: Chen L designed the overall concept and contributed to the writing, and editing of the manuscript, and review of the literature.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li Chen, Doctor, MD, PhD, Doctor, Department of Gastroenterology, Ruijin Hospital, Shanghai JiaoTong University, School of Medicine, No. 999 Xiwang Road, Jiading District, Shanghai 201801, China. drchenli@163.com
Received: October 23, 2023
Peer-review started: October 23, 2023
First decision: November 22, 2023
Revised: November 27, 2023
Accepted: December 12, 2023
Article in press: December 12, 2023
Published online: December 27, 2023
Processing time: 62 Days and 14.8 Hours
Core Tip

Core Tip: The nomenclature for non-alcoholic fatty liver disease has undergone name changes twice in a span of three years. However, there exist significant disparities and some consensus between the transition from metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease. Clarifying these discrepancies would greatly benefit clinical practice and trials.